Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2010 Feb;49(2):373-81.
doi: 10.1093/rheumatology/kep361. Epub 2009 Dec 14.

Development and initial validation of the localized scleroderma skin damage index and physician global assessment of disease damage: a proof-of-concept study

Affiliations

Development and initial validation of the localized scleroderma skin damage index and physician global assessment of disease damage: a proof-of-concept study

Thaschawee Arkachaisri et al. Rheumatology (Oxford). 2010 Feb.

Abstract

Objective: To develop and assess the psychometric properties of the Localized Scleroderma (LS) Skin Damage Index (LoSDI) and Physician Global Assessment of disease Damage (PGA-D).

Methods: Damage was defined as irreversible/persistent changes (>6 months) due to previous active disease/complications of therapy. Eight rheumatologists assessed the importance of 17 variables in formulating the PGA-D/LoSDI. LS patients were evaluated by two rheumatologists using both tools to assess their psychometric properties. LoSDI was calculated by summing three scores for cutaneous features of damage [dermal atrophy (DAT), subcutaneous atrophy (SAT) and dyspigmentation (DP)] measured at 18 anatomic sites. Patient GA of disease severity (PtGA-S), Children's Dermatology Life Quality Index (CDLQI) and PGA-D were recorded at the time of each examination.

Results: Thirty LS patients (112 lesions) and nine patient-visit pairs (18 lesions) were included for inter- and intra-rater reliability study. LoSDI and its domains DAT, SAT, DP and PGA-D demonstrated excellent inter- and intra-rater reliability (reliability coefficients 0.86-0.99 and 0.74-0.96, respectively). LoSDI correlated moderately with PGA-D and poorly with PtGA-S and CDLQI. PGA-D correlated moderately with PtGA-S, but poorly with CDLQI.

Conclusions: To complete the LS Cutaneous Assessment Tool (LoSCAT), we developed and evaluated the psychometric properties of the LoSDI and PGA-D in addition to the LS Skin Severity Index (LoSSI). These instruments will facilitate evaluation of LS patients for individual patient management and clinical trials. LoSDI and PGA-D demonstrated excellent reliability and high validity. LoSCAT provides an improved understanding of LS natural history. Further study in a larger group of patients is needed to confirm these preliminary findings.

PubMed Disclaimer

Figures

F<sc>ig</sc>. 1
Fig. 1
Localized Scleroderma Skin Damage domains distribution. Bars represent the frequencies of each domain score. Distribution recorded by two raters (A and B) from 112 cutaneous surface anatomic sites examined.
F<sc>ig</sc>. 2
Fig. 2
LoSDI distribution. Bars represent LoSDI scores recorded by two raters (A and B) from 39 patient-visits.
F<sc>ig</sc>. 3
Fig. 3
Scatter plot showing the correlation between the LoSDI and PGA-D. Spearman's correlation coefficient = 0.58 (P < 0.001).
F<sc>ig</sc>. 4
Fig. 4
LoSCAT.

Similar articles

Cited by

References

    1. Torres JE, Sanchez JL. Histopathologic differentiation between localized and systemic scleroderma. Am J Dermatopathol. 1998;20:242–5. - PubMed
    1. Peterson LS, Nelson AM, Su WP, Mason T, O’Fallon WM, Gabriel SE. The epidemiology of morphea (localized scleroderma) in Olmsted County 1960–1993. J Rheumatol. 1997;24:73–80. - PubMed
    1. Arkachaisri T, Pino S. Localized scleroderma severity index and global assessments: a pilot study of outcome instruments. J Rheumatol. 2008;35:650–7. - PubMed
    1. Arkachaisri T, Vilaiyuk S, Li SC, et al. The Localized Scleroderma Skin Severity Index (LoSSI) and Physician Global Assessment of Disease Activity: a work-in-progress toward the development of localized scleroderma outcome measures. J Rheumatol. 2009;(in press) - PMC - PubMed
    1. Marzano AV, Menni S, Parodi A, et al. Localized scleroderma in adults and children. Clinical and laboratory investigations on 239 cases. Eur J Dermatol. 2003;13:171–6. - PubMed

Publication types